

Table 1. Demographic, clinical and laboratory features at diagnosis.

	Total (n=23) no. (%)	Typical (n=15) no. (%)	KD (n=8) no. (%)	P value
Demographics				
Female	10 (43.5)	8 (53.3)	2 (25)	0.379
Ethnicity				
Chinese	13 (56.5)	6 (40.0)	7 (87.5)	0.121
Malay	4 (17.4)	4 (26.7)	0 (0)	
Indian	3 (13)	3 (20.0)	0 (0)	
Others	3 (13)	2 (13.3)	1 (12.5)	
Age at onset, years	3.8 (0.6–11.6)	11.4 (3.9–12.8)	0.5 (0.3–1.7)	<0.001
Age at diagnosis, years	3.9 (0.6–11.9)	11.4 (3.9–13.5)	0.5 (0.4–1.8)	<0.001
Duration from onset to diagnosis, months	1.0 (0.6–3.1)	1.0 (0.2–6.0)	1.0 (0.8–1.9)	0.975
Duration of follow-up, years	4.0 (0.7–6.1)	4.9 (0.7–6.2)	1.3 (0.2–5.0)	0.532
Clinical features				
Fever	15 (65.2)	7 (46.7)	8 (100)	0.019
Weight loss	4 (17.4)	3 (20.0)	1 (12.5)	1.000
Malaise	2 (8.7)	2 (13.3)	0 (0)	0.526
Musculoskeletal symptoms	0 (0)	0 (0)	0 (0)	NA
Neurological symptoms	11 (47.8)	10 (66.7)	1 (12.5)	0.027
Headache	6 (26.1)	6 (40.0)	0 (0)	0.058
Syncope	0 (0)	0 (0)	0 (0)	NA
Altered mental status	6 (26.1)	5 (33.3)	1 (12.5)	0.369
Meningoencephalitis	3 (13.0)	3 (20.0)	0 (0)	0.526
Seizures	3 (13.0)	3 (20.0)	0 (0)	0.526
Stroke	5 (21.7)	5 (33.3)	0 (0)	0.122
Claudication	0 (0)	0 (0)	0 (0)	NA
Pulmonary symptoms	2 (8.7)	1 (6.7)	1 (12.5)	1.000
Heart failure, cardiomyopathy	2 (8.7)	1 (6.7)	1 (12.5)	1.000

Table 1. Demographic, clinical and laboratory features at diagnosis. (Cont'd).

	Total (n=23) no. (%)	Typical (n=15) no. (%)	KD (n=8) no. (%)	P value
Gastrointestinal symptoms	8 (34.8)	4 (26.7)	4 (50)	0.371
Eye symptoms	0 (0)	0 (0)	0 (0)	NA
Renal involvement	4 (17.4)	4 (26.7)	0 (0)	0.257
Decreased/absent pulses	0 (0)	0 (0)	0 (0)	NA
Systolic BP discrepancy in arms ≥ 20 mmHg	2 (8.7)	1 (6.7)	1 (12.5)	0.297
Bruits	4 (17.4)	4 (26.7)	0 (0)	0.257
Hypertension	9 (39.1)	7 (46.7)	2 (25)	0.543
Conjunctival injection	6 (28.1)	1 (6.7)	5 (62.5)	0.009
Mucosal changes	5 (21.7)	0 (0)	5 (62.5)	0.002
Rash	6 (26.1)	2 (13.3)	4 (50.0)	0.131
Cervical lymphadenopathy	3 (13.0)	0 (0)	3 (37.5)	0.032
Extremity changes	4 (17.4)	0 (0)	4 (50.0)	0.008
Laboratory findings				
Anaemia present	15 (65.2)	7 (46.7)	8 (100)	0.019
Haemoglobin (g/dL)	11.1 (9.7–13.1)	12.6 (10.9–13.3)	9.6 (8.9–10.7)	0.002
WBC ($\times 10^9/L$)	10.4 (7.7–15.3)	8.4 (7.2–10.4)	19.5 (15.2–36.0)	<0.001
Platelet ($\times 10^9/L$)	377 (248–532)	361 (218–463)	564 (314–718)	0.115
CRP (ng/L)	31.5 (5.4–139.1)	6.8 (1.9–33.2)	143.0 (80.8–173.9)	<0.001
ESR (mm/h)	41.5 (9.0–87.8)	31.0 (6.0–87.0)	82.0 (43.0–98.0)	0.046
ANA ≥ 160	2 (8.6) [n=17]	2 (13.4)	0 (0) [n=2]	0.860
Positive Mantoux test	4 (50) [n=8]	4 (50) [n=8]	NA	NA
Positive IGRA	1 (7.1) [n=14]	1 (6.7) [n=13]	0 (0) [n=1]	1.000

ANA: antinuclear antibodies; BP: blood pressure; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; IGRA: interferon-gamma release assay; KD: Kawasaki disease; WBC: white blood cells

Musculoskeletal symptoms include arthralgia, arthritis, myalgia, back pain; gastrointestinal symptoms exclude vomiting that was due to neurological conditions. Hypertension refers to Stage 1 or 2 hypertension by American Academy of Pediatrics 2017 definition. Mucosal changes include red lips or strawberry tongue. Extremity changes include desquamation, oedema and palmar erythema. Values are presented as absolute numbers (%) or medians (25th–75th percentiles).